Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors. 1998

L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK. Linda_Bristow@merck.com

The putative D3 receptor agonist, (+)-PD 128907, is widely used to study the functional relevance of D3 receptors in vivo. Given that non-selective D2/3/4 receptor agonists serve as effective discriminative stimuli in rats we have trained animals to discriminate (+)-PD 128907 (30 microg kg(-1), s.c.) from saline and examined the pharmacological specificity of the response. Consistent with a D3 receptor mediated response, the non-selective D2/3 receptor agonist apomorphine and the D3 preferring agonists 7-OH-DPAT and (-) quinpirole generalised to the cue whilst the D2/3 receptor antagonists haloperidol, raclopride, spiperone and (+)-butaclamol antagonised drug lever responding. In contrast, the D1 selective agonist (+/-)-SKF 81297 and D1/5 selective antagonist, R-(+)-SCH 23390 had no effect. Results also suggest that presynaptic dopamine receptors are involved. Thus the dopamine depleting agent alpha-methyl-p-tyrosine potentiated the effects of a submaximal dose of (+)-PD 128907 whereas amphetamine failed to generalise per se and blocked (+)-PD 128907 lever selection. However, studies using subtype selective antagonists argue against a role for the D3 receptor. Thus the 10-fold selective D2 receptor antagonist L-741,626 blocked the (+)-PD 128907 discriminative stimulus whereas L-745,829 and GR 103,691, antagonists > 40 and > 100-fold selective for D3 receptors, failed to modify the response. These results suggest that presynaptic D2 receptors mediate the discriminative stimulus properties of (+)-PD 128907 and highlight the lack of selectivity of (+)-PD 128907 for D3 receptors in vivo.

UI MeSH Term Description Entries
D008297 Male Males
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D004192 Discrimination, Psychological Differential response to different stimuli. Discrimination, Psychology,Psychological Discrimination
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001578 Benzopyrans Compounds with a core of fused benzo-pyran rings. Benzopyran,Chromene,Chromenes
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017448 Receptors, Dopamine D2 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES. Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2
D050637 Receptors, Dopamine D3 A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain. Dopamine D3 Receptors,Dopamine D3 Receptor,Dopamine Receptor D3,Receptor, Dopamine-D3,Dopamine-D3 Receptor
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
February 1997, European journal of pharmacology,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
September 2001, Neuropharmacology,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
September 2000, Behavioural pharmacology,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
December 1996, Psychopharmacology,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
January 2005, Neuropharmacology,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
December 1995, The Journal of pharmacology and experimental therapeutics,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
December 1997, Journal of neurochemistry,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
December 1986, European journal of pharmacology,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
January 1995, Life sciences,
L J Bristow, and G P Cook, and S Patel, and N Curtis, and I Mawer, and J J Kulagowski
July 1998, Psychopharmacology,
Copied contents to your clipboard!